newsfilter
← Latest News
GlobeNewswire·

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion